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Andrea Markkula1, Maria Simonsson1, Christian Ingvar2, Carsten Rose3 and Helena Jernström1*Abstract
Background: In breast cancer, high levels of the inflammatory cytokine interleukin-6 (IL-6) have been associated
with disease-free survival and treatment resistance. Increased serum levels of IL-6 have been correlated with
increased levels of NF-κβ and aromatase expression in adipose tissue. Several IL6 single nucleotide polymorphisms
have been associated with breast cancer prognosis, but the impact may differ depending on tumour oestrogen
receptor (ER) status. This translational study investigated the association between IL6 genotypes, ER-status, and
treatment on the risk of early events among breast cancer patients.
Methods: The study included 634 25- to 99-year-old primary breast cancer patients in Sweden from 2002–2008.
Genotyped IL6 single nucleotide polymorphisms rs1800797, rs1800796, rs1800795, and rs2069849 were analysed
separately and as diplotypes. Disease-free survival was assessed for 567 patients. Clinical data, patient-, and
tumour-characteristics were obtained from questionnaires, patient charts, population registries, and pathology reports.
Results: The median follow-up time was 5.1 years. IL6 diplotype was not associated with early events for all 567
patients, but AGCC/AGCC diplotype-carriers with ER-negative tumours had an increased risk, (adjusted Hazard Ratio
(HR) = 5.91, 95% CI: 1.28–27.42). Any C-carriers (rs1800795) with ER-negative tumours had a higher risk of early events
than GG-carriers with ER-negative tumours, (adjusted HR = 3.76, 95% CI: 1.05–13.43), particularly after radiotherapy
(adjusted HR = 7.17, 95% CI: 1.16–32.28). Irrespective of ER-status, chemotherapy-treated Any C-carriers had a higher risk
of early events than GG-carriers (adjusted HR = 3.42, 95% CI: 1.01–11.54).
Conclusions: The main finding of the present study was that IL6 genotype was strongly associated with early events
among patients with ER-negative tumours, particularly among radiotherapy-treated patients, and among
chemotherapy-treated patients irrespective of ER-status. The high risk for early events observed in these subgroups of
patients suggests that combined information on IL6 genotype, tumour ER-status, and breast cancer treatment may
represent a tool for identifying patients who require more personalised treatment.
Keywords: Breast cancer, IL6, Oestrogen receptor, Chemotherapy, Radiotherapy, Treatment resistanceBackground
Breast cancer is the most prevalent type of cancer among
women and the primary cause of cancer death among
women worldwide [1]. Breast cancer treatment resistance
is common and increases mortality [2]. Novel prognostic
and treatment-predictive markers may lead to more perso-
nalised breast cancer treatment and improved prognosis.* Correspondence: helena.jernstrom@med.lu.se
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unless otherwise stated.In breast cancer patients, a high level of the inflamma-
tory cytokine interleukin-6 (IL-6) has been associated with
increased tumour stage, lymph node infiltration, recur-
rence, and treatment resistance [3-5]. Increased serum
levels of IL-6 has been correlated with increased levels of
NF-κβ, which may represent a mechanism for tumour re-
sistance to chemotherapy and radiotherapy [6]. Further,
IL-6 has been shown to stimulate aromatase expression in
adipose tissue; aromatase expression subsequently stim-
ulates oestrogen synthesis, potentially contributing to breast
cancer progression [7].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2407/14/759Several IL6 single nucleotide polymorphisms (SNPs)
have been associated with breast cancer risk and progno-
sis. An IL6 haplotype that consists of the SNPs rs1800797
(−596A >G), rs1800796 (−572G >C), −373 [10A/11 T],
and rs1800795 (−174G > C) was associated with reduced
disease-free survival among breast cancer patients [8]. In a
previous study, postmenopausal women with the SNP
rs1800797 AA genotype had an increased risk of breast
cancer, even if they had not recently been exposed to hor-
mones [9]. Further, patients with oestrogen receptor (ER)-
positive tumours and the SNP rs1800797 GG genotype
had reduced disease-free survival compared to patients
with the CC or GC genotypes [8].
The well-studied SNP rs1800795/-174 G > C that is lo-
cated in the promoter region of IL6 has been associated
with fatigue and survival among breast cancer patients
[8,10-12], and the effects of this SNP appear to vary ac-
cording to tumour ER-status [8,10]. The relationship be-
tween genotype and plasma levels of IL-6 appears to be
complex. The −174 C-allele has been associated with in-
creased IL-6 and C-reactive protein (CRP) levels, par-
ticularly in inflammatory conditions [13-15]; however,
conflicting results have been reported [16,17].
High levels of circulating IL-6 are associated with fatigue
and depression among breast cancer patients [6], and de-
pression is associated with reduced breast cancer survival
[18]. Antidepressant treatment reduced IL-6 levels in de-
pressed patients [19] and increased adherence to adjuvant
breast cancer treatment [20]. In addition, antidepressant
treatment has been hypothesised to increase survival
among depressed cancer patients [21].
To identify novel breast cancer markers of possible
prognostic or treatment-predictive importance among
breast cancer patients, investigations of the combined
effects of antidepressant use, breast cancer treatment,
ER-status, and IL6 genotype on breast cancer prognosis
are necessary. We hypothesised that IL6 genotype can
affect the risk of early events and treatment response
and that the impact of this genotype is further modified
by ER-status. Hence, the aim of this study was to inves-
tigate the impact of the IL6 SNPs rs1800797, rs1800796,
rs1800795, rs2069849 and IL6 diplotypes based on these




Beginning in October 2002, women who were diagnosed
with a first breast cancer at the Skåne University Hospital
in Lund, Sweden were invited preoperatively to participate
in the ongoing prospective BC-blood study. The Skåne
University Hospital in Lund serves nearly 300,000 in-
habitants. Since patients are not referred to other hospitals
for surgery, the cohort is considered population-based.During the time the cohort was compiled, 1,090 patients
received breast cancer surgery at the hospital. Approxi-
mately 58% of these patients were included in the study.
Patients were missed primarily due to a lack of available
research nurses. The included patients were similar to the
non-included patients with respect to age and hormone
receptor status [22]. Patients with a prior history of breast
cancer or another cancer diagnosis within the previous
ten years were excluded. The majority of the patients who
were diagnosed in Lund were ethnic Swedes; however,
ethnicity information was not obtained during this study.
This paper presents data collected from 634 patients
who initiated treatment between October 2002 and
October 2008. Treatment was administered according to
the standard of care at Skåne University Hospital. The
patients were asked to complete questionnaires prior to
surgery, three to six months after surgery and one, two,
three, five, seven, and nine years after surgery. The follow-
up rates in the present cohort were high [23]. Written
informed consent was obtained from all patients, and
the study was approved by the Lund University ethics
committee (Dnr 75–02, 37–08, and 658–09).
During the preoperative visit, blood samples were col-
lected for genotyping. The research nurses also measured
body weight, height, and waist and hip circumferences
during the preoperative visit. The volume of each breast
was measured using plastic cups, as previously described
[24]. The waist circumference was measured at the umbil-
icus; the hip circumference was measured at the widest
part between the hip and trochanter major. The question-
naire included questions regarding the date of surgery, re-
productive history, exogenous hormone use, smoking
history (i.e., yes/no/occasional smoker) and alcohol con-
sumption. Patients who identified themselves as regular
smokers and occasional smokers during the preoperative
visit or at any subsequent visit were classified as smokers.
A body mass index (BMI) cut-off value of 25 kg/m2 was
used, according to the WHO’s classification of overweight
[25]. Central obesity was considered to be present if the
waist-to-hip ratio (WHR) was above 0.85 [25]. Questions
regarding alcohol consumption frequency were based on
the alcohol use disorders identification test (AUDIT) [26].
A breast volume cut-off of 850 ml was chosen based on
a previous publication [27]. Mammography-detected tu-
mours in patients aged 45–74 years at the time of diag-
nosis were considered to be screening-detected. Patients
within this age category were invited to mammography
screening in Sweden during the study inclusion period.
Antidepressant use was coded as a dummy variable
based on the information obtained from the preopera-
tive questionnaire [28].
Information regarding the type of adjuvant treatment,
sentinel node biopsy results, axillary lymph node dissec-
tion and type of surgery was collected from patient charts.
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tionnaires and was recorded up to the time of the last
follow-up appointment or death, prior to any event.
Data on invasive tumour size, histological type and
grade, and number of involved axillary lymph nodes
were obtained from each patient’s pathology report. ER
and progesterone receptor (PgR) status were deter-
mined as previously described [29,30].
The tumours were analysed in the Department of
Pathology at Skåne University Hospital in Lund. Informa-
tion concerning breast cancer events, including local or
regional recurrence, new breast cancer, or distant metasta-
ses, was obtained from patient charts, pathology reports
and the Regional Tumour Registry. The date of death was
obtained from the Swedish Population Registry.Genotyping
Genomic deoxyribonucleic acid (DNA) was extracted
from the leukocyte portion of whole blood using a Wizard
Genomic DNA Purification Kit (Promega, Madison, WI,
USA). Genotyping was performed at the Region Skåne
Competence Centre (RSKC Malmö) of Malmö University
Hospital in Malmö, Sweden. The SNPs rs1800797,
rs1800796, rs1800795, and rs2069849 were analysed
via matrix-assisted laser desorption/ionisation time-of-flight
mass spectrometry using a Sequenom MassARRAY®
platform (Sequenom, San Diego, CA, USA) and iPLEX
reagents, according to the manufacturers’ protocol.
Sequenom MassARRAY® software (Sequenom) was used
for multiplex SNP analysis design. Over 10% of the sam-
ples were run in duplicate, with a concordance of 100%.IL6 diplotype construction
Each SNP was cross-tabulated against the other three
SNPs. This procedure demonstrated that certain combi-
nations did not exist or were very rare. Therefore, we
constructed the haplotypes and diplotypes based on the
most likely combinations. The IL6 diplotype consisted
of four IL6 SNPs: rs1800797 (−596A > G), rs1800796
(−572G > C/-634C > G), rs1800795 (−174 G/C), and
rs2069849 (C/T coding exon 5). Diplotype variants that
were present in less than 5% of the patients were classi-
fied as rare variants and combined into a single group
termed ‘rare diplotypes.’ IL6 diplotype information was
missing for nine patients. Rs1800797 analysis failed for
five patients; of these cases, three SNPs could be im-
puted based on rs1800795, as the R2 between these two
SNPs was 0.966. Consequently, while rs1800795 analysis
failed for four patients, two SNPs could be imputed
based on rs1800797. The two remaining SNPs lacked in-
formation related to both Rs1800797 and Rs1800795
and could therefore not be imputed. Rs1800796 analysis
failed for seven patients.Data analyses
Statistical analyses were performed using IBM SPSS
Statistics 19.0 (Chicago, IL, USA). Each patient’s BMI
was calculated by dividing weight in kilograms by the
square of patient height in meters (kg/m2). The WHR
was calculated as waist circumference divided by hip
circumference.
IL6 genotype was analysed in relation to tumour and
patient characteristics. IL6 gentype was analysed in rela-
tion to patient characteristics (i.e., age at diagnosis,
weight, height, BMI, WHR, age at menarche, and total
breast volume) using the non-parametric Kruskal-Wallis
test because these variables were continuous and not
normally distributed. Chi-square analyses were used to
investigate the relationship between IL6 genotype and
the categorical variables breast volume ≥850 ml (yes/no),
parous (yes/no), preoperative use of antidepressants
(yes/no), any hormone replacement therapy use (HRT)
(yes/no), preoperative smoking (yes/no), smoking at any
visit (yes/no), alcohol consumption frequency, screening-
detected tumour (yes/no), invasive tumour size (in
situ, ≤20 mm, 21–50 mm, ≥51 mm, skin or muscle in-
volvement, or 21 mm or larger), histological grade (I-III or
III), axillary lymph node involvement (0, 1–3, 4+, or any
axillary lymph node involvement (yes/no)), ER-status
(positive/negative), PgR status (positive/negative), and the
combination variables ER- and PgR-positive (yes/no), ER-
and PgR-negative (yes/no), ER-positive and PgR-negative
(yes/no), and ER-negative and PgR-positive (yes/no).
To analyse breast cancer-free survival, patients were
followed from inclusion to the first breast cancer event.
Patients without events were followed until the last
follow-up or death prior to January 1, 2013. Of 634 pa-
tients, 567 were included in the survival analyses of IL6
diplotype and 574 patients were included in the survival
analyses of rs1800795.
For the univariable survival analysis, the Log-Rank test
was used to analyse the risk of early cancer events in rela-
tion to IL6 genotype, ER-status, and breast cancer treat-
ment. Due to the small number of homozygous rs1800795
minor allele carriers, the G/C and C/C genotypes were
combined into a single “Any C” genotype for the survival
analyses. For the multivariable analysis, Cox regression
was used to calculate Hazard Ratios (HRs) in relation to
rs1800795, adjusting for age (linear), invasive tumour size
(≥21 mm or muscular or skin involvement), axillary lymph
node involvement (yes/no), and histological grade III
(yes/no). Since few patients exhibited an invasive tumour
size ≥51 mm or muscular or skin involvement, these
patients were combined with the patients with invasive
tumour sizes between 21 and 50 mm in the multivariable
analyses. In the multivariable analyses of rs1800795, a cat-
egorical variable that combined rs1800795 and ER-status
was used. Adjustments were made using breast volume,
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variables. Breast volume was not normally distributed
and was therefore transformed using the natural loga-
rithm (ln). Prior power calculations that assumed 600
patients with an accrual interval of 6 years, an additional
follow-up time of 2 years and 30% of patients with a
variant allele demonstrated that the study was able to
detect true HRs between 0.722 and 1.440 with 80%
power and an α of 5% [31]. Further, simulations with
80% failure rates were also performed, demonstrating
that the study had sufficient power to detect an in-
creased HR of 1.9 with a genotype frequency of 30%.
A P-value <0.05 was considered significant. All P-values
were two-tailed. Since this was an exploratory study,
nominal P-values are presented without adjustments for
multiple testing. The report is based on the REMARK
criteria [32].
Results
IL6 htSNP analyses were performed for 634 patients.
Genotype information was missing for nine women. Five
different haplotypes and 11 different diplotypes were iden-
tified in the cohort. The two most common haplotypes
were AGCC (45.3% of patients) and GGGC (46.6% of pa-
tients). The three most common diplotypes were AGCC/
GGGC, AGCC/AGCC, and GGGC/GGGC (38.2, 23.2,
and 23.5% of patients, respectively). The eight diplotype
variants that were present in less than 5% of the patients
were classified as rare variants and combined into a single
group termed ‘rare diplotypes’.
Patient and tumour characteristics
Patient characteristics for the 567 patients with diplotype
information and the 574 patients with information on
rs1800795 genotype who were included in the survival
analyses are presented in Table 1. Tumour characteris-
tics for the 567 patients with diplotype information and
the 574 patients with information on rs1800795 geno-
type who were included in the survival analyses are pre-
sented in Table 2. Patient characteristics for all 634
patients, for the 567 patients with diplotype information,
and the 574 patients with information on rs1800795
genotype who were included in the survival analyses are
presented in Additional file 1. Tumour characteristics
for all patients included the 592 patients who had not
received preoperative treatment, for the 567 patients in-
cluded in the diplotype survival analyses, and for the 574
patients included in the rs1800795 survival analyses are
presented in Additional file 2. A borderline significant
association was observed between carrying the AGCC/
GGGC diplotype and having a non-screening-detected
tumour (P = 0.063). The GGGC/GGGC diplotype was
borderline significantly associated with ER and PgR
negativity (P = 0.055). For rs1800795, GC-carriers had aborderline significant increased risk of an invasive tumour
size ≥21 mm (P = 0.061).
Early events in relation to IL6 diplotype
Patients who had received preoperative treatment (n = 42),
who were diagnosed with carcinoma in situ (n = 14), and/
or who had metastases detected earlier than three months
after study inclusion (n = 2) were excluded from the sur-
vival analyses. A flowchart of the patients included and ex-
cluded in the analyses is presented in Figure 1. Among the
567 remaining patients, 86 were diagnosed with some type
of breast cancer event (i.e., ipsi/contralateral, regional,
or distant metastasis) during the 9-year follow-up time
period; 54 of these patients had distant metastases. The
median follow-up time was 5.1 years (IQR 3.0–7.1 years).
Among these 567 patients, IL6 diplotype was not associ-
ated with early events in a univariable model (Figure 2a;
Log Rank 3 df; P = 0.83) or in a multivariable model when
adjusting for tumour size, axillary lymph node involve-
ment, age, and histological grade III (adjusted HR = 1.14;
95% CI 0.62–2.10; P = 0.67). The addition of ER-status,
BMI, WHR or breast volume to the model did not signifi-
cantly change the results.
Early events in relation to IL6 diplotype and ER-status
Among the 73 patients with ER-negative tumours, pa-
tients with the AGCC/AGCC or AGCC/GGGC genotypes
had an increased risk of early events (Figure 2b; Log Rank
3 df; P = 0.014). In a multivariable model, this difference
was only significant for the AGCC/AGCC diplotype (ad-
justed HR = 5.91; 95% CI 1.28–27.42; P = 0.023) compared
to the GGGC/GGGC diplotype. When the dichotomous
variable breast volume ≥850 ml was added to the model,
the association between IL6 AGCC/AGCC diplotype and
risk of early events was strengthened (adjusted HR = 7.29;
95% CI 1.54–34.53; P = 0.012). The results remained es-
sentially the same when BMI or WHR was added to the
model.
Among the 492 patients with ER-positive tumours, the
IL6 diplotype was not associated with the risk of early
events in a univariable model (Log Rank 3 df; P = 0.50)
or in a multivariable model (adjusted HR = 0.73; 95% CI
0.37–1.45; P = 0.36). The addition of body constitution
to the model did not essentially change the results.
Early events in relation to IL6 diplotype, ER-status, and
breast cancer treatment
Chemotherapy-treated patients with ER-negative tumours
who had either an AGCC/GGGC or an AGCC/AGCC
diplotype had an increased risk of early events (Log Rank
3 df; P = 0.031). This association was not observed among
chemotherapy-treated patients with ER-positive tumours
(Log Rank 3 df; P = 0.95). In a multivariable model of
patients with ER-negative tumours who had received





Stratified according to IL6 diplotype* Patients included
in the rs1800795
survival analyses
Stratified accoding to rs1800795**





















n= 567 130 (22.9) 221 (39.0) 131 (23.1) 85 (15.0) 574 181 (31.5) 257 (44.8) 136 (23.7)
Age at diagnosis,
yrs
59.7 (51.8-66.3) - 60.5 (49.2-66.7) 59.5 (51.4-66.7) 59.8 (53.8-66.4) 58.4 (51.1-65.2) 59.8 (52.0-66.4) - 60.5 (49.9-67.1) 59.5 (52.2-66.4) 59.8 (53.8-66.3)
Weight, kgs 68.0 (61.0-76.7) 2 69.0 (62.0-81.3) 67.0 (60.0-75.0) 68.0 (61.0-78.5) 68.3 (62.0-77.6) 68.0 (61.0-76.9) 2 69.0 (61.9-80.0) 67.1 (60.4-75.0) 69.0 (61.0-78.9)
Height, m 1.66 (1.62-1.70) 1 1.66 (1.62-1.71) 1.65 (1.62-1.69) 1.65 (1.62-1.70) 1.67 (1.60-1.70) 1.66 (1.62-1.70) 1 1.66 (1.60-1.71) 1.66 (1.62-1.69) 1.66 (1.62-1.70)
BMI, kgs/m2 24.6 (22.3-27.7) 3 25.2 (22.9-29.1) 24.3 (21.9-26.9) 24.6 (22.4-28.6) 24.4 (22.2-28.2) 24.6 (22.3-27.9) 3 25.2 (22.6-28.7) 24.4 (22.1-27.4) 24.6 (22.4-28.8)
Breast volume 1000 (600–1450) 75a 1000 (700–1538) 950 (600–1450) 988 (600–1450) 900 (585–1563) 1000 (600–1450) 75a 950 (650–1400) 1000 (625–1563) 1000 (600–1450)
Breast volume
≥850 ml
281 (57.1) 75a 68 (60.7) 110 (55.6) 65 (59.1) 38 (52.8) 286 (57.3) 75a 86 (55.8) 132 (57.4) 68 (59.1)
Waist-Hip Ratio 0.84 (0.78-0.89) 2 0.84 (0.78-0.90) 0.83 (0.78-0.88) 0.84 (0.79-0.89) 0.83 (0.78-0.89) 0.84 (0.78-0.89) 2 0.83 (0.78-0.90) 0.83 (0.78-0.88) 0.84 (0.79-0.89)
Age at
menarche, yrs
13 (12–14) 3 13 (12–14) 13 (12–14) 14 (13–14) 13 (12–14) 13 (12–14) 3 13 (12–14) 13 (12–14) 14 (13–14)
Parous 485 (85.5) - 111 (85.4) 192 (86.9) 108 (82.4) 74 (87.1) 490 (85.4) - 156 (86.2) 222 (86.4) 112 (82.4)
Alcohol use 1 1
Never 62 (11.0) 19 (14.6) 23 (10.4) 15 (11.5) 5 (6.0) 62 (10.8) 23 (12.8) 24 (9.3) 15 (11.0)
Not more than
once a month
149 (26.3) 37 (28.5) 57 (25.8) 34 (26.0) 21 (25.0) 154 (26.9) 48 (26.7) 69 (26.8) 37 (27.2)
2-4 times per
month
216 (38.2) 41 (31.5) 84 (38.0) 54 (41.2) 37 (44.0) 217 (37.9) 64 (35.6) 97 (37.7) 56 (41.2)
2-3 times per
week
110 (19.4) 27 (20.8) 51 (23.1) 19 (14.5) 13 (15.5) 111 (19.4) 34 (18.9) 58 (22.6) 19 (14.0)
4 or more times
per week
29 (5.1) 6 (4.6) 6 (2.7) 9 (6.9) 8 (9.5) 29 (5.1) 11 (6.1) 9 (3.5) 9 (6.6)
Pre-operative
smoker
121 (21.3) - 22 (16.9) 48 (21.7) 30 (22.9) 21 (24.7) 121 (21.1) - 33 (18.2) 57 (22.2) 31 (22.8)
Smoker at any
visit






















56 (9.9) - 14 (10.8) 21 (9.5) 16 (12.2) 5 (5.9) 57 (9.9) - 18 (9.9) 23 (8.9) 16 (11.8)
Ever use of
HRT, %
263 (46.5) 1 54 (41.9) 102 (46.2) 70 (53.4) 37 (43.5) 267 (46.6) 1 77 (42.8) 118 (45.9) 72 (52.9)
Screening
detected tumor
289 (60.3) 88b 59 (56.7) 102 (54.8) 78 (68.4) 50 (66.7) 293 (60.5) 90b 84 (56.8) 129 (59.2) 80 (67.8)
*9 patients lacked genotype information.
**2 patients lacked genotype information.
***IQR Interquartile range.
aAnalysis included women who had not gone through breast surgery before diagnosis.


















Table 2 Tumour characteristics for all patients included in the survival analyses, and stratified according to IL6 diplotype (A) and rs1800795 (B) (number of
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567 130 (22.9) 221 (39.0) 131 (23.1) 85 (15.0) 574 181 (31.5) 257 (44.8) 136 (23.7)
Preoperative interstitial
laser thermotherapy




1 0 0 0 1 1 0 1 0
Neoadjuvant therapy 26 (4.3) 8 (5.7) 9 (3.9) 5 (3.6) 4 (4.4) 26 (4.3) 9 (4.6) 12 (4.4) 5 (3.5)
No preoperative
treatment
567 130 (22.9) 221 (39.0) 131 (23.1) 85 (15.0) 574 181 (31.5) 257 (44.8) 136 (23.7)
Invasive tumour size (pT) - -
≥21 mm (≥2) 150 (26.5) 28 (21.5) 69 (31.2) 30 (22.9) 23 (27.1) 151 (26.3) 40 (22.1) 80 (31.1) 31 (22.8)
In Situ - - - - - - - - -
≤20 mm (1) 417 (73.5) 102 (78.5) 152 (68.8) 101 (77.1) 62 (72.9) 423 (73.7) 141 (77.9) 177 (68.9) 105 (77.2)
21-50 mm (2) 141 (24.9) 27 (20.8) 64 (29.0) 27 (20.6) 23 (27.1) 142 (24.7) 39 (21.5) 75 (29.2) 28 (20.6)
51- mm (3) 8 (1.4) 1 (0.8) 4 (1.8) 3 (2.3) 0 8 (1.4) 1 (0.6) 4 (1.6) 3 (2.2)
skin or muscle involvement
(4)






217 (38.4) 41 (31.8) 89 (40.3) 50 (38.5) 37 (43.5) 221 (38.6) 62 (34.4) 108 (42.0) 51 (37.8)
0 348 (61.6) 88 (68.2) 132 (59.7) 80 (61.5) 48 (56.5) 351 (61.4) 118 (65.6) 149 (58.0) 84 (62.2)
1-3 163 (28.8) 29 (22.5) 70 (31.7) 36 (27.7) 28 (32.9) 167 (29.2) 46 (25.6) 84 (32.7) 37 (27.4)
4+ 54 (9.6) 12 (9.3) 19 (8.6) 14 (10.8) 9 (10.6) 54 (9.4) 16 (8.9) 24 (9.3) 14 (10.4)
Histological grade 1 1
Grade III 111 (19.6) 30 (23.1) 49 (22.3) 18 (13.7) 14 (16.5) 113 (19.7) 37 (20.4) 57 (22.3) 19 (14.0)
I 154 (27.4) 29 (22.3) 64 (29.1) 40 (30.5) 22 (25.9) 157 (27.4) 43 (23.8) 72 (28.1) 42 (30.9)
II 298 (53.0) 71 (54.6) 107 (48.6) 73 (55.7) 49 (57.6) 303 (52.9) 101 (55.8) 127 (49.6) 75 (55.1)


















Table 2 Tumour characteristics for all patients included in the survival analyses, and stratified according to IL6 diplotype (A) and rs1800795 (B) (number of
patients who had not received preoperative treatment indicated in boldface) (Continued)
Hormone receptor status
ER+ 492 (87.1) 2 106 (81.5) 192 (86.9) 118 (90.8) 76 (90.5) 499 (87.2) 2 152 (84.4) 224 (87.2) 123 (91.1)
PgR+ 394 (69.7) 2 81 (62.3) 151 (68.3) 98 (75.4) 64 (76.2) 399 (69.8) 2 119 (66.1) 179 (69.6) 101 (74.8)
ER+PgR+ 390 (69.0) 2 80 (61.5) 149 (67.4) 97 (74.6) 64 (76.2) 395 (69.1) 2 118 (65.6) 177 (68.9) 100 (74.1)
ER+PgR- 102 (18.1) 2 26 (20.0) 43 (19.5) 21 (16.2) 12 (14.3) 104 (18.2) 2 34 (18.9) 47 (18.3) 23 (17.0)
ER-PgR- 69 (12.2) 2 23 (17.7) 27 (12.2) 11 (8.5) 8 (9.5) 69 (12.1) 2 27 (15.0) 31 (12.1) 11 (8.1)
ER-PgR+ 4 (0.7) 2 1 (0.8) 2 (0.9) 1 (0.8) 0 4 (0.7) 2 1 (0.6) 2 (0.8) 1 (0.7)
*9 patients lacked genotype information.



















42 patients excluded due to                       
preoperative treatment 
9 patients excluded due to missing 
genotype information
634 patients included in the study and analyzed 
for patient and tumor characteristics 
567 patients analyzed for patient and tumor 
characteristics, and early events
14 patients excluded due to
carcinoma in situ
2 patients excluded due to metastatic
spread within 3 months of inclusion
492 patients with 
ER+ tumors
73 patients with ER -
tumors
2 patients excluded due to missing data 
regarding ER -status
49 patients ever received chemotherapy
54 patients ever received radiation therapy
122 patients with no endocrine treatment
123 patients treated with AI and tamoxifen
307 patients ever treated with tamoxifen
186 patients ever treated with AI
184 patients treated with tamoxifen but no AI
63 patients treated with AI but no tamoxifen
58 patients ever received chemotherapy
290 patients ever received radiation therapy
Figure 1 Flow chart of the patient selection process.
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http://www.biomedcentral.com/1471-2407/14/759chemotherapy, patients with the AGCC/AGCC diplotype
had an increased risk of early events compared to patients
with the GGGC/GGGC diplotype (adjusted HR = 17.28;
95% CI 1.51–198.51; P = 0.022). The addition of body
constitution to the model did not essentially change the
results, except for the case of the dichotomous variable
WHR > 85, which weakened the association (adjusted
HR = 9.00; 95% CI 0.71–114.02; P = 0.090).
Radiotherapy-treated patients with ER-negative tumours
who had either an AGCC/GGGC or an AGCC/AGCC
diplotype had an increased risk of early events (Log
Rank 3 df; P = 0.041). No such association was observed
for radiotherapy-treated patients with ER-positive tu-
mours (Log Rank 3 df; P = 0.58). In a multivariable
model of patients with ER-negative tumours who had
received radiotherapy, the association between the
AGCC/AGCC diplotype and the risk of early events
was borderline significant (adjusted HR = 5.71; 95% CI0.98–33.33; P = 0.053). Similar results were obtained
when body constitution was added to the model.
Among patients who had not received chemotherapy
and patients who had not received radiotherapy, IL6
diplotype was not associated with early events in any uni-
variable or multivariable models.
Early events in relation to the four individual IL6 SNPs
To investigate whether any of the SNPs were driving the
results, each SNP was examined. No association was ob-
served between rs1800796 and rs2069849 and risk of early
events when stratifying according to ER-status or breast
cancer treatment (data not shown). However, both
rs1800795 Any C-carriers and rs1800797 Any A-carriers
had an increased risk of early events among various sub-
groups of patients. Since rs1800795 and rs1800797 had
an r2 = 0.966, we chose to continue our analyses with
the most studied SNP: rs1800795. The following survival
ab
Figure 2 Breast cancer-free survival in relation to IL6 diplotype. Kaplan-Meier estimates of breast cancer-free survival in relation to IL6
diplotype. Since this is an ongoing cohort, there are fewer patients with longer follow-up times. a) Breast cancer-free survival among all patients
with invasive tumours (Log Rank 3 df; P = 0.83). The adjusted HR was 1.14 (95% CI 0.62–2.10; P = 0.67). b) Breast cancer-free survival among
patients with invasive ER-negative tumours (Log Rank 3 df; P = 0.014). The adjusted HR was 5.91 (95% CI 1.28–27.42; P = 0.023).
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http://www.biomedcentral.com/1471-2407/14/759analyses were based on 574 patients as information on
rs1800795 genotype was available for an additional seven
patients with ER-positive tumours.Early events in relation to rs1800795
Among all patients, rs1800795 was not associated with
early events in a univariable (Figure 3a; Log Rank 1 df;
ab
Figure 3 Breast cancer-free survival in relation to rs1800795 genotype. Kaplan-Meier estimates of breast cancer-free survival in relation to
rs1800795 genotype. Since this is an ongoing cohort, there are fewer patients with longer follow-up times. a) Breast cancer-free survival among
all patients with invasive tumours (Log Rank 1 df; P = 0.69). The adjusted HR was 1.11 (95% CI 0.69–1.77; P = 0.67). b) Breast cancer-free survival
among patients with invasive ER-negative tumours (Log Rank 1 df; P = 0.014). The adjusted HR was 3.76 (95% CI 1.05–13.43; P = 0.041).
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http://www.biomedcentral.com/1471-2407/14/759P = 0.69) or multivariable model (adjusted HR = 1.11;
95% CI 0.69–1.77; P = 0.67). Adjusting for ER-status or
body constitution generated similar results.
Early events in relation to rs1800795 and ER-status
Among patients with ER-negative tumours, Any C-
carriers had an increased risk of early events comparedto GG-carriers (Figure 3b; Log Rank 1 df; P = 0.014).
This difference was also observed using a multivariable
model (adjusted HR = 3.76; 95% CI 1.05–13.43; P = 0.041).
The results were essentially the same when body constitu-
tion was added to the model.
Among patients with ER-positive tumours, rs1800795
was not associated with early events in a univariable
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http://www.biomedcentral.com/1471-2407/14/759model (Log Rank 1 df; P = 0.38) or in a multivariable
model (adjusted HR = 0.79; 95% CI 0.47–1.33; P = 0.37).
The addition of body constitution to the model yielded
similar results.
Early events in relation to rs1800795, ER-status, and
breast cancer treatment
Irrespective of ER-status, chemotherapy-treated Any C-
carriers had an increased risk of early events compared
to GG-carriers (Figure 4a; Log Rank 1 df; P = 0.030).
This difference was also observed using a multivariable
model (adjusted HR = 3.42; 95% CI 1.01–11.54; P = 0.048).
When the dichotomous variable breast volume ≥850 ml
was added to the model, the association between being an
Any C-carrier and having an increased risk of early events
was strengthened (adjusted HR = 3.71; 95% CI 1.08–12.75;
P = 0.037). The addition of ER-status or other body
constitution-related parameters to the model did not es-
sentially change the results.
Radiotherapy-treated Any C-carriers with ER-negative
tumours had an increased risk of early events compared
to GG-carriers (Figure 4b; Log Rank 3 df; P < 0.0001).
This finding was also observed using a multivariable
model (adjusted HR = 7.17; 95% CI 1.16–32.28; P = 0.010).
Similar results were obtained when body constitution
was added to the model. No such association was ob-
served among radiotherapy-treated Any C-carriers with
ER-positive tumours.
Among patients who had not received chemotherapy
and patients who had not received radiotherapy, rs1800795
was not associated with early events in any univariable
or multivariable models.
Early events in relation to rs1800795 and antidepressant
treatment
At the preoperative visit, 56 of the patients included in
the survival analyses were undergoing some type of pre-
scribed antidepressant treatment. Three of these patients
ceased treatment during the first year after their breast
cancer diagnosis. During the first year after diagnosis, 23
additional patients started antidepressant treatment. Any
C-carriers (n = 383) were more likely to have started
than to have ceased antidepressant treatment during the
first year after their breast cancer diagnosis (McNemar’s
test P = 0.001). For GG-carriers (n = 176), this association
was not significant (McNemar’s test P = 0.11); however,
no significant differences were observed between Any
C-carriers and GG-carriers.
No association was observed between antidepressant
treatment prior to any breast cancer event and risk of
early events, either at the preoperative visit (Log Rank 1
df; P = 0.61) or during any visit up to the 1-year visit
(Log Rank 1 df; P = 0.32). Multivariable models yielded
similar results.Discussion
The present study investigated the impact of IL6 genotype
on early events and treatment response in an ongoing co-
hort of breast cancer patients. The main finding was that
IL6 genotype was strongly associated with early events
among patients with ER-negative tumours, especially in
radiotherapy-treated patients, and among chemotherapy-
treated patients irrespective of ER-status. To our know-
ledge, the association of IL6 genotype with disease-free
survival and treatment response in relation to tumour
ER-status has not been previously investigated in a large
population-based cohort of breast cancer patients.
The high-risk AGCC/AGCC diplotype contains the high-
risk genotypes of the SNPs rs1800795 and rs1800797. The
association between risk of early events and diplotype ap-
pears to be primarily driven by the SNPs rs1800795 and
rs1800797, as no association was observed between the
SNPs rs1800796 and rs2069849 and disease-free survival.
Therefore, the discussion will focus primarily on the asso-
ciation between rs1800795 and disease-free survival.
Some studies reported that the rs1800795 C-allele was
associated with reduced systemic levels of IL-6 [16,17].
However, several studies found that the lower levels of
IL-6 that were observed among C-allele carriers com-
pared to G-allele carriers were increased and surpassed
the levels observed in G-allele carriers when both geno-
types were subjected to inflammatory stimuli [14,33,34].
Therefore, we hypothesise that the C-allele is associated
with increased levels of IL-6; however, this association
only exists in the presence of inflammatory stimuli, such
as ER-negativity, radiotherapy or chemotherapy. A tenta-
tive explanation for the association between IL6 genotype
and inflammatory stimuli might be found in a differential
reduction in the methylation of the IL6 promoter, because
rs1800795 has been reported to be in linkage with the
rs2069845 CpG site [35].
In the present study, IL6 genotype predicted disease-
free survival only among patients with ER-negative tu-
mours, unless the patients had received chemotherapy. A
previous study demonstrated that IL-6 constitutively acti-
vates the NF-κβ pathway, which subsequently drives fur-
ther IL-6 production, creating a positive feedback loop
[36]. As reviewed by Shostack et al., NF-κβ plays a crucial
role in breast cancer progression by stimulating prolifera-
tion and preventing apoptosis. NF-κβ is more frequently
constitutively activated in ER-negative tumours than in
ER-positive tumours, and ERα has been shown to repress
NF-κβ activation [37]. Further, NF-κβ inhibition has been
shown to inhibit proliferation of ER-negative cells [38]. If
Any C-carriers with ER-negative tumours have an in-
creased level of IL-6, an associated increase in NF-κβ may
explain the impaired prognosis among those patients.
Among patients who had received chemotherapy, Any
C-carriers had an over 3-fold increased risk of events
ab
Figure 4 Breast cancer-free survival in different treatment groups in relation to rs1800795 genotype. a) Kaplan-Meier estimates of breast
cancer-free survival in relation to rs1800795 genotype among chemotherapy-treated patients (Log Rank 1 df; P = 0.030). The adjusted HR was 3.42
(95% CI 1.01–11.54; P = 0.048). Since this is an ongoing cohort, there are fewer patients with longer follow-up times. b) Kaplan-Meier estimates of
breast cancer-free survival in relation to rs1800795 genotype among radiotherapy-treated patients (Log Rank 3 df; P < 0.0001). The adjusted HR
was 7.17 (95% CI 1.16–32.28; P = 0.010). Since this is an ongoing cohort, there are fewer patients with longer follow-up times.
Markkula et al. BMC Cancer 2014, 14:759 Page 13 of 16
http://www.biomedcentral.com/1471-2407/14/759compared to GG-carriers, regardless of their ER-status.
Chemotherapy has been shown to increase IL-6 levels in
breast cancer patients and to activate NF-κβ [39,40]. IL-6
levels and NF-κβ activation are associated with chemo-
therapy resistance, and inhibition of NF-κβ has sensitisedchemotherapy resistant cell lines to chemotherapy [6,41].
The increased levels of IL-6 in Any C-carriers that occur
in response to chemotherapy-associated inflammation and
the related increase in NF-κβ could explain the ele-
vated risk of events among chemotherapy-treated Any
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hibitors of NF-κβ or IL-6 could be of interest for this
subgroup of patients.
In the present study, radiotherapy-treated Any C-carriers
with ER-negative tumours had an over 7-fold increased risk
of events compared to GG-carriers. IL-6 levels and NF-κβ
activation have been linked to radiotherapy resistance [6].
In addition, in a randomised control trial, radiotherapy
conferred significantly smaller improvements in recur-
rence control for patients with ER-negative tumours than
for patients with ER-positive tumours [42]. A majority of
the early events that occurred among Any C-carriers with
ER-negative tumours were distant metastases (9 out of 13
events). Hence, the increased risk of this group cannot be
explained by local radiotherapy resistance. Radiation in-
duces inflammatory signalling, which lasts long beyond
the initial radiation-induced burst [43]. This signalling is
mainly executed via the activation of NF-κβ, but IL-6
levels have also been shown to increase [44]. According to
our previously stated hypothesis, radiotherapy-induced
inflammation would be particularly harmful for Any C-
carriers with ER-negative tumours, as this inflammation
represents an additional inflammatory stimulus that in-
duces Any C-carriers to release large amounts of systemic
IL-6, explaining the impaired prognosis among those pa-
tients. Inhibitors of NF-κβ or IL-6 could be of interest for
this subgroup of patients; previous studies reported prom-
ising results after treating radiotherapy resistance with
NF-κβ inhibitors [44].
The addition of body constitution to the multivariable
models modified the association between IL6 genotype and
disease-free survival in some subgroups. IL-6 levels and
body constitution are closely linked. Body constitution-
related parameters, such as obesity, a high WHR, and a
large breast volume, are associated with breast cancer
prognosis [27,45,46]. This association is believed to be me-
diated by chronic inflammation [47]. Our group recently
reported that the inflammation-associated COX2 rs5277
SNP impacted breast cancer prognosis differently depend-
ing on tumour ER-status, type of breast cancer treatment,
and body constitution [48]. However, no association was
observed between rs5277 on chromosome 1 and rs1800795
on chromosome 7 (data not shown). Hence, the findings of
the present study are independent from the previous study.
Although no association was observed between anti-
depressant use and genotype in the present study, the
relationship between genotype and depression could not
be assessed using our questionnaire. Depression is esti-
mated to be underdiagnosed in cancer patients [49]. To
properly investigate the association between genotype
and depression, it would be necessary to collect additional
information on depressive symptoms.
The results of the present study are in contrast to
the results of two previous studies [8,10], in whichchemotherapy-treated GG-carriers with ER-positive
tumours had a shorter disease-free survival than Any
C-carriers. However, these studies investigated this associ-
ation in two smaller cohorts of chemotherapy-treated pa-
tients. One cohort had a median axillary lymph node
involvement of 14 nodes, and in the other cohort, 81% of
patients had ≥10 positive lymph nodes. The present study
and these previous studies are not comparable, because
our cohort comprises a population-based series of breast
cancer patients in which the majority of patients were
node negative.
The present study did not have access to systemic
IL-6 levels. However, intrapersonal IL-6 levels vary
greatly depending on the time of day, food intake, re-
cent exercise routines, et cetera [50]. Stable genomic
information on inflammatory tendency may be super-
ior for assessing ongoing systemic inflammation, as
it is not affected by daily fluctuations. This study is
population-based, and the included patients were simi-
lar to non-included patients with respect to age and
hormone receptor status [22]. SNP genotyping is con-
sidered reliable in the present study, as over 10% of
the samples were run in duplicate, with a concordance
of 100%. In the present study, the vast majority of pa-
tients were ethnic Swedes. Studies of the association be-
tween IL6 genotype and breast cancer prognosis in other
ethnic groups are warranted.
Since the median follow-up time was only 5 years, the
long-term effects of IL6 genotype on disease-free sur-
vival could not be evaluated. The estimated failure rates
in the previous power calculation exceeded the observed
failure rates; these failure rates may have influenced the
power of this study. In addition, this study assessed a
number of variables and some of the findings may be at-
tributable to chance. The results must be confirmed in in-
dependent cohorts.Conclusions
The main finding of the present study was that IL6 geno-
type was strongly associated with early events among
patients with ER-negative tumours, particularly among
radiotherapy-treated patients, and among chemotherapy-
treated patients irrespective of ER-status. We hypothesise
that the mechanism that underlies this observation is that
the rs1800795 C-allele is associated with increased sys-
temic levels of IL-6 in the presence of inflammatory stim-
uli, such as ER-negativity, radiotherapy, and chemotherapy.
The high risk for early events observed in certain sub-
groups of patients suggests that combined information
on IL6 genotype, tumour ER-status, and breast cancer
treatment may represent a tool for identifying patients
who require more personalised treatment, potentially
using inhibitors of NF-κβ or IL-6.
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